Advanced search
Publication Cover
Drug Delivery Volume 25, 2018 - Issue 1
Submit an article Journal homepage
1,214
Views
10
CrossRef citations to date
0
Altmetric
Research Article

Modification of translationally controlled tumor protein-derived protein transduction domain for improved intranasal delivery of insulin

Hae-Duck BaeGraduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul, KoreaView further author information
,
Joohyun LeeGraduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul, KoreaView further author information
,
Kyu-Yeon JunGraduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul, KoreaView further author information
,
Youngjoo KwonGraduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul, KoreaView further author information
&
Kyunglim LeeGraduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul, KoreaCorrespondence[email protected]
View further author information
Pages 1025-1032 | Received 28 Jan 2018, Accepted 09 Apr 2018, Published online: 24 Apr 2018

References

  • Arora P, Sharma S, Garg S. (2002). Permeability issues in nasal drug delivery. Drug Discov Today 7:967–75.
  • Bae HD, Lee K. (2013). On employing a translationally controlled tumor protein-derived protein transduction domain analog for transmucosal delivery of drugs. J Control Release 170:358–64.
  • Bae H-D, Lee J, Jin X-H, et al. (2016). Potential of translationally controlled tumor protein-derived protein transduction domains as antigen carriers for nasal vaccine delivery. Mol Pharmaceutics 13:3196–205.
  • Duan X, Mao S. (2010). New strategies to improve the intranasal absorption of insulin. Drug Discov Today 15:416–27.
  • El-Andaloussi S, Holm T, Langel U. (2005). Cell-penetrating peptides: mechanisms and applications. Cpd 11:3597–611.
  • Gros E, Deshayes S, Morris MC, et al. (2006). A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction. Biochimica Et Biophysica Acta 1758:384–93.
  • Guo Z, Peng H, Kang J, et al. (2016). Cell-penetrating peptides: Possible transduction mechanisms and therapeutic applications. Biomed Rep 4:528–34.
  • He H, Sheng J, David AE, et al. (2013). The use of low molecular weight protamine chemical chimera to enhance monomeric insulin intestinal absorption. Biomaterials 34:7733–43.
  • Jarver P, Langel U. (2004). The use of cell-penetrating peptides as a tool for gene regulation. Drug Discov Today 9:395–402.
  • Kamei N, Morishita M, Eda Y, et al. (2008). Usefulness of cell-penetrating peptides to improve intestinal insulin absorption. J Control Release 132:21–5.
  • Khafagy el S, Morishita M, Takayama K. (2010). The role of intermolecular interactions with penetratin and its analogue on the enhancement of absorption of nasal therapeutic peptides. Int J Pharm 388:209–12.
  • Khafagy E-S, Morishita M, Isowa K, et al. (2009). Effect of cell-penetrating peptides on the nasal absorption of insulin. J Control Release 133:103–8.
  • Kim M, Kim M, Kim HY, et al. (2011a). A protein transduction domain located at the NH2-terminus of human translationally controlled tumor protein for delivery of active molecules to cells. Biomaterials 32:222–30.
  • Kim M, Maeng J, Jung J, et al. (2011b). Design and evaluation of variants of the protein transduction domain originated from translationally controlled tumor protein. Eur J Pharm Sci 43:25–31.
  • Kristensen M, de Groot AM, Berthelsen J, et al. (2015a). Conjugation of cell-penetrating peptides to parathyroid hormone affects its structure, potency, and transepithelial permeation. Bioconjugate Chem 26:477–88.
  • Kristensen M, Franzyk H, Klausen MT, et al. (2015b). Penetratin-mediated transepithelial insulin permeation: importance of cationic residues and pH for complexation and permeation. Aaps J 17:1200–9.
  • Landreh M, Alvelius G, Willander H, et al. (2012). Insulin solubility transitions by pH-dependent interactions with proinsulin C-peptide. FEBS J 279:4589–97.
  • Liang JF, Yang VC. (2005). Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem Biophys Res Commun 335:734–8.
  • Marttin E, Verhoef JC, Romeijn SG, et al. (1995). Effects of absorption enhancers on rat nasal epithelium in vivo: release of marker compounds in the nasal cavity. Pharm Res 12:1151–7.
  • McMartin C, Hutchinson LEF, Hyde R, et al. (1987). Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J Pharma Sci 76:535–40.
  • Merkus FWHM, Schipper NGM, Hermens WAJJ, et al. (1993). Absorption enhancers in nasal drug delivery: efficacy and safety. J Control Release 24:201–8.
  • Morris MC, Depollier J, Mery J, et al. (2001). A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 19:1173–6.
  • Morris MC, Deshayes S, Heitz F, et al. (2008). Cell-penetrating peptides: from molecular mechanisms to therapeutics. Mol Biol Cell 100:201–17.
  • Nagahara H, Vocero-Akbani AM, Snyder EL, et al. (1998). Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 4:1449–52.
  • Sakuma S, Suita M, Masaoka Y, et al. (2010). Oligoarginine-linked polymers as a new class of penetration enhancers. J Control Release 148:187–96.
  • Zatsepin T, Turner J, Oretskaya T, et al. (2005). Conjugates of oligonucleotides and analogues with cell penetrating peptides as gene silencing agents. Cpd 11:3639–54.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.